Serial Number
88225549
Owner
PEBBLE LABS INC.Attorney
David S. KerrFirst Use Date
Jan 7, 2018
Filing Date
Dec 11, 2018
PEBBLE LABS Trademark
Serial Number: 88225549 • Registration: 5819332
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
DAVID S. KERR BERG HILL GREENLEAF RUSCITTI LLP
1712 PEARL ST.
BOULDER, CO 80302
UNITED STATES
Trademark Details
Filing Date
December 11, 2018
Registration Date
July 30, 2019
First Use Anywhere
January 7, 2018
First Use in Commerce
January 7, 2018
Published for Opposition
May 14, 2019
Cancellation Date
February 13, 2026
Goods & Services
Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Design and development of biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals for use in pharmaceuticals, biotechnology, and medical and diagnostic applications; Research and development of biopharmaceutical compounds; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit mosquito populations; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit mosquito populations; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce eukaryotic-like mRNA; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce commercial compounds; Research and development of genetically engineered organisms, namely, genetically engineered algae that produce that produce waxes; Research and development of pharmaceuticals, therapeutics, and biologics; Research and development of new biological products for therapeutic use